期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis 被引量:1
1
作者 lisa m lundquist Sabrina W Cole martha L Sikes 《World Journal of Orthopedics》 2014年第4期504-511,共8页
Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs(DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis(RA) as monotherapy or in combinatio... Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs(DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis(RA) as monotherapy or in combination with methotrexate or other non-biologic DMARD. Tofacitinib, an orally administered Janus kinase(JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type Ⅰcytokine receptors family and γ-chain cytokines to paired JAK1/JAK3 receptors. The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials have been conducted to evaluate the safety and efficacy of tofacitinib under the oral rheumatoid arthritis triaL s(ORAL) series. This review describes the pharmacology of the novel agent, tofacitinib, and details the safety and efficacy data of the ORAL trials. 展开更多
关键词 Tofacitinib RHEUMATOID ARTHRITIS JANUS KINASE INHIBITOR
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部